Raloxifene

Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Keoxifene, Raloxifeno, Raloxifenum and Evista. Its PubChem CID is 5035.

CAS No 84449-90-1
Molecular Formula C28H27NO4S
Molecular Weight 473.6 g/mol
Synonyms [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone

Frequently Asked Questions